Waltz Quoted on ROI from Anti-Fraud Efforts Under President Trump
20 March 2017
Bloomberg BNA
Partner Judy Waltz was quoted in a Bloomberg BNA article, “Trump Budget Would Boost Spending to Fight Medicare, Medicaid Fraud,” covering the ideal return on investment from anti-fraud efforts, and the integrity of the Trump administration’s anti-fraud program as a whole.
Waltz explains that the support for program integrity “is because the [Health Care Fraud and Abuse Control] program has been able to demonstrate a good return on investment, both in actual dollars and in the nonquantifiable deterrent side as well.”
She continues to say that, however, “with the administration’s statements about reducing regulatory burdens, there may be less emphasis on fraud, waste and abuse allegations that reflect regulatory noncompliance [in the future].”
Waltz explains that the support for program integrity “is because the [Health Care Fraud and Abuse Control] program has been able to demonstrate a good return on investment, both in actual dollars and in the nonquantifiable deterrent side as well.”
She continues to say that, however, “with the administration’s statements about reducing regulatory burdens, there may be less emphasis on fraud, waste and abuse allegations that reflect regulatory noncompliance [in the future].”
People
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."